Navigation Links
Scientists discover new drug candidates for cystic fibrosis and other diseases
Date:11/1/2011

Bethesda, MDA new discovery by Californian scientists may lead to a pharmaceutical breakthrough for a wide range of illnesses that involve the hydration of cells that line the inner surfaces of our body's organs and tissues. In a new report appearing in the FASEB Journal (http://www.fasebj.org), the researchers describe how they used high-throughput screening to identify small-molecule drug candidates which help cells bypass defective channels that normally move salt and water through cell membranes. These drug candidates work by activating an alternative chloride channel called "TMEM16A" that might be effective in treating conditions such as cystic fibrosis, dry eye and dry mouth diseases and slow-transit constipation.

"Further pre-clinical development of the chloride channel activators identified in our study may lead to new drug therapies for cystic fibrosis, dry eye and mouth syndromes, and certain types of constipation," said Alan S. Verkman, M.D., Ph.D., study author from the Department of Medicine at the University of California, San Francisco.

Verkman and colleagues discovered these compounds by using high-throughput screening, in which more than 100,000 drug-like compounds were tested for their ability to activate the TMEM16A channel. Active compounds coming from the screen were further improved and tested in cell and mouse models. These compounds were found to help facilitate salt and water movement, making them promising drug candidates.

"Scientists have known for decades that cells have more than one way to move salt and water. Indeed, over the years many useful drugs have been developed that influence these movements in the heart and kidneys," said Gerald Weissmann, M.D., Editor-in-Chief of the FASEB Journal. "This discovery is important not only because it identifies a new channel present all over the body, but finds a promising agent to activate it. As further drug candidates are devised to target TMEM16A, this work may lead to clinical advances of major significance."


'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert

Related biology news :

1. Gladstone scientists identify protein form linked to Huntingtons disease
2. Scientists chart gene expression in the brain across lifespan
3. Scientists measure dream content for the first time
4. A*STAR scientists first to identify stem cell key to lung regeneration
5. UK scientists come together to help feed the 7 billion
6. Geoscientists find key to why some patients get infections from cardiac implants
7. Scientists determine family tree for most-endangered bird family in the world
8. Philadelphia scientists to be honored with the John Scott Award
9. 46 outstanding life scientists elected to EMBO membership
10. Scientists report major advance in human antibody therapy against deadly Hendra virus
11. Magnifying research: Scientists team together to upgrade supercomputer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/30/2017)... 30, 2017 The research team of The ... (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery ... of speed and accuracy for use in identification, crime investigation, immigration ... ... A research team ...
Breaking Biology News(10 mins):
(Date:10/10/2017)... , ... October 10, 2017 ... ... cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing ... HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO ... Diego Rotary Club. The event entitled “Stem Cells and Their Regenerative ... attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced ... the NIH to develop RealSeq®-SC (Single Cell), expected to ... profiling small RNAs (including microRNAs) from single cells using ... highlights the need to accelerate development of approaches to ... "New techniques for measuring levels of ...
(Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon Program Committee ... honoring scientists who have made outstanding contributions to analytical chemistry and applied ... the world’s leading conference and exposition for laboratory science, which will be held ...
Breaking Biology Technology: